Interleukin-2 based therapy for kidney cancer.
In summary, IL-2 based therapy remains the basis for treatment of metastatic renal cell cancer. Un-answered questions remain in the development of regimens that exceed a mean response rate of 20%. Additionally, there may be differences among the histologic subtypes of renal cell cancer that predispose to response or lack there of to immunotherapy, and this is being further explored. As can be noted from the studies presented in this paper, there are numerous variations on the regimens for IL-2 based therapy. Current recommendations are to use the simplest and most feasible in a given institution. Certainly high dose IL-2 remains the standard regimen to which all others are measured.
Dutcher
Janice P
JP
Our Lady of Mercy Cancer Center, New York Medical College, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis
D000970:Antineoplastic Agents; D007376:Interleukin-2